196 related articles for article (PubMed ID: 37605497)
21. Potential role of immune cell genetic variants associated with tumor microenvironment response in laryngeal squamous cell carcinoma (LSCC) in terms of clinicopathological features.
Horozoglu C; Sonmez D; Demirkol S; Hakan MT; Kaleler I; Hepokur C; Verim A; Yaylim I
Pathol Res Pract; 2021 Dec; 228():153665. PubMed ID: 34717150
[TBL] [Abstract][Full Text] [Related]
22. The B7 family revisited.
Greenwald RJ; Freeman GJ; Sharpe AH
Annu Rev Immunol; 2005; 23():515-48. PubMed ID: 15771580
[TBL] [Abstract][Full Text] [Related]
23. Decreased levels of alternative co-stimulatory receptors OX40 and 4-1BB characterise T cells from head and neck cancer patients.
Baruah P; Lee M; Odutoye T; Williamson P; Hyde N; Kaski JC; Dumitriu IE
Immunobiology; 2012 Jul; 217(7):669-75. PubMed ID: 22204816
[TBL] [Abstract][Full Text] [Related]
24. Immunohistochemical expression of histone modification pattern in adult glioblastoma.
Archana B; D'Cruze L; Sundaram S; Ramanathan K; Ganesh K
J Cancer Res Ther; 2024 Jan; 20(1):52-56. PubMed ID: 38554298
[TBL] [Abstract][Full Text] [Related]
25. Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice.
Li J; Semple K; Suh WK; Liu C; Chen F; Blazar BR; Yu XZ
Biol Blood Marrow Transplant; 2011 Jul; 17(7):962-9. PubMed ID: 21447398
[TBL] [Abstract][Full Text] [Related]
26. Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models.
Shin JH; Park HB; Oh YM; Lim DP; Lee JE; Seo HH; Lee SJ; Eom HS; Kim IH; Lee SH; Choi K
Blood; 2012 Jun; 119(24):5678-87. PubMed ID: 22538857
[TBL] [Abstract][Full Text] [Related]
27. Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3.
Rapoport BL; Steel HC; Benn CA; Nayler S; Smit T; Heyman L; Theron AJ; Hlatshwayo N; Kwofie LLI; Meyer PWA; Anderson R
Front Oncol; 2023; 13():1097309. PubMed ID: 37064132
[TBL] [Abstract][Full Text] [Related]
28. Higher preoperative serum levels of PD-L1 and B7-H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma.
Fukuda T; Kamai T; Masuda A; Nukui A; Abe H; Arai K; Yoshida K
Cancer Med; 2016 Aug; 5(8):1810-20. PubMed ID: 27292320
[TBL] [Abstract][Full Text] [Related]
29. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
30. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S; Yim S; Park H
Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
[TBL] [Abstract][Full Text] [Related]
31. 2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses.
Liu D; Krummey SM; Badell IR; Wagener M; Schneeweis LA; Stetsko DK; Suchard SJ; Nadler SG; Ford ML
J Exp Med; 2014 Feb; 211(2):297-311. PubMed ID: 24493803
[TBL] [Abstract][Full Text] [Related]
32. By Binding CD80 and CD86, the Vaccinia Virus M2 Protein Blocks Their Interactions with both CD28 and CTLA4 and Potentiates CD80 Binding to PD-L1.
Kleinpeter P; Remy-Ziller C; Winter E; Gantzer M; Nourtier V; Kempf J; Hortelano J; Schmitt D; Schultz H; Geist M; Brua C; Hoffmann C; Schlesinger Y; Villeval D; Thioudellet C; Erbs P; Foloppe J; Silvestre N; Fend L; Quemeneur E; Marchand JB
J Virol; 2019 Jun; 93(11):. PubMed ID: 30918073
[TBL] [Abstract][Full Text] [Related]
33. Polymorphisms in the CD28/CTLA4/ICOS genes: role in malignant melanoma susceptibility and prognosis?
Bouwhuis MG; Gast A; Figl A; Eggermont AM; Hemminki K; Schadendorf D; Kumar R
Cancer Immunol Immunother; 2010 Feb; 59(2):303-12. PubMed ID: 19672595
[TBL] [Abstract][Full Text] [Related]
34. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Butte MJ; Keir ME; Phamduy TB; Sharpe AH; Freeman GJ
Immunity; 2007 Jul; 27(1):111-22. PubMed ID: 17629517
[TBL] [Abstract][Full Text] [Related]
35. Regulation of Retinal Development via the Epigenetic Modification of Histone H3.
Watanabe S; Murakami A
Adv Exp Med Biol; 2016; 854():635-41. PubMed ID: 26427469
[TBL] [Abstract][Full Text] [Related]
36. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.
Pratt D; Dominah G; Lobel G; Obungu A; Lynes J; Sanchez V; Adamstein N; Wang X; Edwards NA; Wu T; Maric D; Giles AJ; Gilbert MR; Quezado M; Nduom EK
Neurosurgery; 2019 Aug; 85(2):280-289. PubMed ID: 30011045
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization of the T cell costimulatory receptors CD28 and CTLA4 in the European sea bass.
González-Fernández C; Esteban MA; Cuesta A
Fish Shellfish Immunol; 2021 Feb; 109():106-115. PubMed ID: 33348036
[TBL] [Abstract][Full Text] [Related]
38. B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma.
Lu Z; Zhao ZX; Cheng P; Huang F; Guan X; Zhang MG; Chen HP; Liu Z; Jiang Z; Zheng ZX; Zou SM; Wang XS
Mod Pathol; 2020 Nov; 33(11):2330-2340. PubMed ID: 32514163
[TBL] [Abstract][Full Text] [Related]
39. Enhanced histone H3 acetylation of the PD-L1 promoter via the COP1/c-Jun/HDAC3 axis is required for PD-L1 expression in drug-resistant cancer cells.
Wang H; Fu C; Du J; Wang H; He R; Yin X; Li H; Li X; Wang H; Li K; Zheng L; Liu Z; Qiu Y
J Exp Clin Cancer Res; 2020 Feb; 39(1):29. PubMed ID: 32024543
[TBL] [Abstract][Full Text] [Related]
40. CTLA4-Ig-Based Bifunctional Costimulation Inhibitor Blocks CD28 and ICOS Signaling to Prevent T Cell Priming and Effector Function.
Goenka R; Xu Z; Samayoa J; Banach D; Beam C; Bose S; Dooner G; Forsyth CM; Lu X; Medina L; Sadhukhan R; Sielaff B; Sousa S; Tao Q; Touw D; Wu F; Kingsbury GA; Akamatsu Y
J Immunol; 2021 Mar; 206(5):1102-1113. PubMed ID: 33495237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
